このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Daito PharmaceuticalLtd マネジメント

マネジメント基準チェック /04

Daito PharmaceuticalLtd'sの CEO はYasunobu Otsugaで、 Aug2012年に任命され、の在任期間は 11.83年です。は、会社の株式の2.39%を直接所有しており、その価値は¥ 829.19M 。経営陣と取締役会の平均在任期間はそれぞれ1.4年と1.4年です。

主要情報

Yasunobu Otsuga

最高経営責任者

n/a

報酬総額

CEO給与比率	n/a
CEO在任期間	11.9yrs
CEOの所有権	2.4%
経営陣の平均在職期間	1.5yrs
取締役会の平均在任期間	1.5yrs

経営陣の近況

Recent updates

CEO（最高経営責任者

Yasunobu Otsuga (74 yo)

11.9yrs

在職期間

Mr. Yasunobu Otsuga has been the President of Daito Pharmaceutical Co., Ltd. since August 2012 and serves as its Chief Executive Officer. Mr. Otsuga Joined Daito Pharmaceutical Co., Ltd.In March 1975. Mr....

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Yasunobu Otsuga	CEO, President & Representative Director	11.9yrs	データなし	2.39% ¥ 828.5m
Hiroshi Matsumori	VP of Business Strategy & Head of Administrative Division and Director	1.5yrs	データなし	0.085% ¥ 29.5m
Kazushige Hizume	Senior Corporate Officer	no data	データなし	0.13% ¥ 43.5m
Masuo Nomura	Director	no data	データなし	0.0072% ¥ 2.5m
Hiroshi Kubota	Senior Corp. Officer	1.5yrs	データなし	データなし
Yutaka Kuwashima	Senior Corporate Officer	no data	データなし	データなし
Masahiro Harai	Exe. Off.	no data	データなし	データなし
Yoji Nakamura	Executive Officer and Deputy Head of Quality & Regulatory Affairs Division	no data	データなし	データなし
Yoshinori Nakajima	Exec. Off.	no data	データなし	データなし
Eiichi Takata	Executive Officer and Head of Research & Development Division	no data	データなし	データなし
Toru Ishida	Exe. Off.	no data	データなし	データなし
Masahiko Mouri	Executive Officer	no data	データなし	データなし

1.5yrs

平均在職期間

70yo

平均年齢

経験豊富な経営陣: 4577の経営陣は経験豊富とはみなされません ( 1.4年の平均在職年数)。これは新しいチームを示唆しています。

取締役

名称	ポジション	在職期間	報酬	所有権
Yasunobu Otsuga	CEO, President & Representative Director	16.9yrs	データなし	2.39% ¥ 828.5m
Hiroshi Matsumori	VP of Business Strategy & Head of Administrative Division and Director	1.5yrs	データなし	0.085% ¥ 29.5m
Kazushige Hizume	Senior Corporate Officer	no data	データなし	0.13% ¥ 43.5m
Masuo Nomura	Director	less than a year	データなし	0.0072% ¥ 2.5m
Hitoshi Hori	Independent External Director	no data	データなし	0.11% ¥ 37.3m
Ichizo Yamamoto	Independent External Director	no data	データなし	データなし
Atsushi Saino	Independent Outside Director	no data	データなし	データなし
Kimiko Komatsu	Independent Outside Director	no data	データなし	データなし

1.5yrs

平均在職期間

68yo

平均年齢

経験豊富なボード: 4577の取締役会は経験豊富ではない ( 1.4年の平均在任期間) ため、新しい取締役会が必要であると考えられます。

Daito PharmaceuticalLtd マネジメント

マネジメント 基準チェック /04

主要情報

経営陣の近況

Daito Pharmaceutical Co.,Ltd., Annual General Meeting, Aug 29, 2023

Less than half of directors are independent

Daito Pharmaceutical Co.,Ltd., Annual General Meeting, Aug 24, 2022

Less than half of directors are independent

Recent updates

New major risk - Revenue and earnings growth

Upcoming dividend of JP¥30.00 per share

Third quarter 2024 earnings released: EPS: JP¥50.14 (vs JP¥56.83 in 3Q 2023)

Daito Pharmaceutical Co.,Ltd. (TSE:4577) announces an Equity Buyback for 350,000 shares, representing 2.23% for ¥1,000 million.

Price target increased by 8.6% to JP¥3,155

Daito Pharmaceutical Co.,Ltd. to Report Q3, 2024 Results on Apr 12, 2024

Second quarter 2024 earnings released: EPS: JP¥50.40 (vs JP¥51.58 in 2Q 2023)

Daito Pharmaceutical Co.,Ltd. (TSE:4577) announces an Equity Buyback for 160,000 shares, representing 1.01% for ¥303.36 million.

Daito Pharmaceutical Co.,Ltd. (TSE:4577) announces an Equity Buyback for 160,000 shares, representing 1.01% for ¥303.36 million.

Daito Pharmaceutical Co.,Ltd. to Report Q2, 2024 Results on Jan 12, 2024

Upcoming dividend of JP¥30.00 per share at 2.8% yield

First quarter 2024 earnings released: EPS: JP¥47.54 (vs JP¥59.74 in 1Q 2023)

Full year 2023 earnings: EPS exceeds analyst expectations

Daito Pharmaceutical Co.,Ltd. to Report Q1, 2024 Results on Oct 12, 2023

Full year 2023 earnings: EPS exceeds analyst expectations

Daito Pharmaceutical Co.,Ltd., Annual General Meeting, Aug 29, 2023

Daito Pharmaceutical Co.,Ltd. to Report Fiscal Year 2023 Results on Jul 14, 2023

Upcoming dividend of JP¥30.00 per share at 2.4% yield

Third quarter 2023 earnings released: EPS: JP¥62.51 (vs JP¥85.94 in 3Q 2022)

Second quarter 2023 earnings released: EPS: JP¥56.74 (vs JP¥69.11 in 2Q 2022)

Now 21% undervalued after recent price drop

Daito Pharmaceutical Co.,Ltd. to Report Q2, 2023 Results on Jan 13, 2023

Upcoming dividend of JP¥30.00 per share

Less than half of directors are independent

First quarter 2023 earnings released: EPS: JP¥65.71 (vs JP¥133 in 1Q 2022)

Daito Pharmaceutical Co.,Ltd. to Report Q1, 2023 Results on Oct 13, 2022

Consensus forecasts updated

Consensus forecasts updated

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Daito Pharmaceutical Co.,Ltd., Annual General Meeting, Aug 24, 2022

Now 22% undervalued after recent price drop

Now 20% undervalued after recent price drop

Daito Pharmaceutical Co.,Ltd. to Report Fiscal Year 2022 Results on Jul 14, 2022

Now 21% undervalued after recent price drop

Upcoming dividend of JP¥35.00 per share

Price target decreased to JP¥4,800

Less than half of directors are independent

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Daito Pharmaceutical Co.,Ltd. to Report Q3, 2022 Results on Apr 14, 2022

Second quarter 2022 earnings: EPS exceeds analyst expectations

Upcoming dividend of JP¥25.00 per share

Price target decreased to JP¥5,100

First quarter 2022 earnings released: EPS JP¥133 (vs JP¥98.06 in 1Q 2021)

Daito Pharmaceutical Co.,Ltd. announced that it expects to receive ¥13.351 million in funding from Daiwa Securities Co., Ltd., Investment Arm

Full year 2021 earnings released: EPS JP¥311 (vs JP¥310 in FY 2020)

Upcoming dividend of JP¥23.00 per share

Third quarter 2021 earnings released

Daito Pharmaceutical Co.,Ltd. to Report Q3, 2021 Results on Apr 14, 2021

New 90-day low: JP¥3,485

New 90-day low: JP¥3,500

Revenue and earnings beat expectations

Revenue and earnings beat expectations

Second quarter 2021 earnings released: EPS JP¥80.36

Daito Pharmaceutical Co.,Ltd. to Report Q2, 2021 Results on Jan 14, 2021

Daito Pharmaceutical Co.,Ltd. to Report Q1, 2021 Results on Oct 13, 2020

CEO（最高経営責任者

在職期間

リーダーシップ・チーム

平均在職期間

平均年齢

取締役

平均在職期間

平均年齢

マネジメント基準チェック /04